Skip to main content
    S

    Sellas Life Sciences Group Inc (SLS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.47
    -0.39 (-4.96%)

    Market Cap: $1.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sellas Life Sciences Group Inc (SLS) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Sellas Life Sciences Group (SLS) to earn -$0.20 per share in the fiscal year ending Dec 31, 2026. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.10.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$0.20
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.10
    EPS consensus, revenue $53.09M
    Next report
    Mar 17, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.20-$0.20 to -$0.201N/AN/A1
    Dec 31, 2027-$0.10-$0.20 to $0.002$53.09M$53.09M to $53.09M1

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.05-$0.05 to -$0.053

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.21.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.20-$0.21-$0.21-$0.21-$0.21N/A
    Fiscal year ending Dec 31, 2027-$0.10-$0.13-$0.13-$0.15-$0.15N/A

    Frequently Asked Questions About SLS

    What is the SLS stock forecast?

    Consensus analyst estimates put Sellas Life Sciences Group's EPS at -$0.20 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from SLS next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.20, with estimates from -$0.20 to -$0.20 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.10, with estimates from -$0.20 to $0.00 from 2 analysts.

    What revenue do analysts expect from Sellas Life Sciences Group next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $53.09M, with estimates from $53.09M to $53.09M.

    How many analysts cover SLS?

    1 analyst estimates EPS for Sellas Life Sciences Group for the fiscal year ending Dec 31, 2026.